跳至主要内容
临床试验/NL-OMON35702
NL-OMON35702已完成不适用

Effects of RAS inhibition on insulin sensitivity and IGF-I bioactivity - RAS inhibition, insulin sensitivity and IGF-I bioactivity

Ikazia Ziekenhuis0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - age 18 * 70 years
  • - impaired fasting glucose (IFG): fasting plasma glucose levels between 5,6 * 6,9 mmol/l (100 * 125 mg/dl) and/or impaired glucose tolerance (IGT): plasma glucose levels between 7,8 * 11,0 mmol/l (140 * 199 mg/dl) after 2 hours on the 75-g oral glucose tolerance test

排除标准

  • - use of RAS inhibitors within 6 weeks prior to inclusion
  • - use of oral glucose-lowering drugs or insulin
  • - use of statins
  • - use of betablockers
  • - use of steroids, hormone replacement therapy or other study medication
  • - contraindication for or intolerant to RAS inhibitors
  • - untreated hypothyroidism or hyperthyroidism
  • - negroid race
  • - pregnancy and breastfeeding
  • - severe renal insufficiency (GFR < 30mL/min) and/or known bilateral renal artery stenosis
  • - hyperpotassemia (potassium > 5,0mmol/L)

研究者

发起方
Ikazia Ziekenhuis

相似试验